Enveric Biosciences, a leading psychedelics biotech company, has presented promising preclinical research on its lead compound EB-003, a non-hallucinogenic DMT analog, at the 7th Neuropsychiatric Drug Summit. The research suggests that EB-003 could be a potential treatment for anxiety and depression, showing positive behavioral outcomes in mouse models.